A practical roadmap for companies preparing the first commercial launch of a medicinal product in Europe.
Obtaining EU Marketing Authorization is a major achievement, but it is only the beginning of the launch journey. National requirements across Member States can significantly impact timelines, especially for companies without established EU affiliates or commercial infrastructure.
When accelerated assessment timelines are combined with risk-minimisation obligations, serialization requirements, and country-specific launch rules, coordination becomes critical to avoid delays at the most sensitive phase: market entry.
What you’ll discover in this case study:
- Why EU-wide approval does not eliminate national regulatory and operational obligations
- The mandatory country-by-country launch requirements that must be in place before placing a product on the market
- How overlooked elements such as serialization or MAH registration can jeopardize timelines
- How to structure a multi-country launch roadmap aligned with the European Commission decision
- How to coordinate regulatory, pharmacovigilance, supply chain, and commercial stakeholders for on-time entry
- How a structured “GloCal” approach enables launch within one month post-approval
Each section reflects hands-on experience managing a first European launch under tight timelines, transforming regulatory complexity into a controlled and synchronized market entry strategy.
